ASCO GU 2024: Updates in the Treatment of Advanced Renal Cell Carcinoma - Episode 2
The expert panel discusses the 8-year follow-up data from CheckMate 214 looking at nivolumab plus ipilimumab in first-line advanced RCC and provide clinical insights on treatment decisions.